Equities Analysts Set Expectations for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Nektar Therapeutics in a research note issued to investors on Tuesday, December 10th. HC Wainwright analyst A. He anticipates that the biopharmaceutical company will post earnings per share of ($0.46) for the year. HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at $0.13 EPS, Q3 2025 earnings at ($0.16) EPS and Q4 2025 earnings at ($0.15) EPS.

Several other equities research analysts have also recently commented on the company. BTIG Research restated a “buy” rating and set a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $4.10.

Nektar Therapeutics Trading Down 2.0 %

Shares of NASDAQ:NKTR opened at $1.00 on Thursday. The company has a market capitalization of $184.46 million, a PE ratio of -1.19 and a beta of 0.57. Nektar Therapeutics has a twelve month low of $0.46 and a twelve month high of $1.93. The firm has a 50 day simple moving average of $1.22 and a 200-day simple moving average of $1.25.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. SG Americas Securities LLC boosted its position in Nektar Therapeutics by 30.4% during the 3rd quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 22,285 shares during the period. Victory Capital Management Inc. bought a new position in Nektar Therapeutics in the 2nd quarter worth approximately $29,000. Valence8 US LP bought a new stake in shares of Nektar Therapeutics during the third quarter valued at approximately $34,000. Jane Street Group LLC increased its position in shares of Nektar Therapeutics by 50.0% during the third quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 30,481 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Nektar Therapeutics in the 3rd quarter valued at $41,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.